National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.
FDA Issues Alert on Counterfeit Botox: What Dermatology Clinicians Need to Know
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
New Data on Retinol: Patricia Farris, MD, Shares Insights on Anti-Aging
The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice
Allergan Aesthetics Launches New Book to Bring More Awareness to Ethics in Aesthetics
Habits, Cultural Norms, and Rapid Advances In Technology Have Dramatically Changed the Aesthetic Medicine Landscape